Company Overview
Tango Therapeutics is a biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer.
Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer.
This includes expanding the universe of precision oncology targets into novel areas such as tumor suppressor gene loss and their contribution to the ability of cancer cells to evade immune cell killing.
Tango’s labs and offices are located at 201 Brookline Avenue, in the vibrant Fenway area of Boston, Massachusetts
Summary
We are seeking a Clinical Supply Manager (CSM) to lead the end-to-end clinical supply management process of our growing clinical portfolio. This role will serve as the primary sponsor contact for external vendors managing the packaging and labeling, storage, distribution, and return/ destruction of clinical supplies.
In a fast-paced, small biotech environment, the CSM will plan, execute and oversee clinical supplies in alignment with trial timelines, budget, regulatory requirements and internal standards. This individual will play a key role in enabling clinical trial start, patient enrollment, and continuous supply as per trial requirements, proactively identifying and mitigating risks, and ensuring compliance of clinical supply with applicable regulations and internal standards.
The ideal candidate is highly collaborative, detail-oriented, and comfortable operating in a hands-on environment, with a focus on building scalable processes, tools, and best practices to support efficient and compliant clinical trial execution.
Your role
- Develop and maintain global clinical supply strategies, including forecasting needs for investigational products, comparators, and co-medications
- Oversee inventory levels at depots and clinical sites, defining resupply strategies based on usage trends to prevent shortages
- Coordinate distribution, importing, and exporting of materials
- Ensure all activities comply with Good Manufacturing Practices (GMP), ICH guidelines, and internal standards
- Manage external vendors (incl. budget), such as Clinical Manufacturing Organizations (CMO), packaging partners and depots
- Track vendor performance using metrics, KPIs, and KRIs
- Act as the primary clinical supplies contact for Clinical Trial Teams (CTT), Chemistry, Manufacturing, and Controls (CMC), and quality assurance (QA)
- Organize and coordinate meetings with key stakeholders, including decision tracking and action item follow-up
- Generate optimal distribution plans and develop tools, forms etc. to track and document end-to-end processes
- Trigger and track shipments of clinical supply from central depot to regional hubs and local depots
- Contribute to Information Response Technology (IRT) set-up, testing and maintenance in close collaboration with relevant CTT functions to ensure efficiency, timeliness and accuracy of clinical supplies management
- Provide input into label text as well as into packaging and labeling materials
- Identify and assesses risks and issues related to clinical supplies, proactively communicate them and lead the development and implementation of mitigation strategies and action plans
- Ensure inspection and audit readiness of clinical supplies; participate in internal audits and inspection from health authorities, as required.
What You Bring
- 5+ years of supply management experience. Experience in leadership preferred
- Bachelor’s degree in Life Sciences, Pharmacy or related field
- Experience working in global clinical development organization
- Experience in Oncology development (preferred)
- Experience in outsourcing and oversight
- Direct experience with health authority inspections of clinical supply management (preferred)
- Knowledge of relevant regulations and guidelines (GMP, ICH guidelines, HSE)
- Knowledge of appropriate supply chain systems used for forecasting and demand planning as well as supply management metrics, KPIs, and KRIs
- Familiarity with other systems used in clinical trials (e.g., CTMS, IRT, eTMF)
- Strong operational excellence with high attention to details
- Strong vendor management and project management skills
- Leadership skills with the ability to lead cross-functional teams
- Strong interpersonal and communication skills
- Strong analytical thinking and decision-making capabilities
We are an equal opportunity employer and value diversity at our company. We do not discriminate on the basis of race, religion, color, national origin, gender, sexual orientation, age, marital status, veteran status, or disability status.
#LI-Hybrid
Skills Required
- 5+ years of supply management experience
- Bachelor's degree in Life Sciences, Pharmacy or related field
- Experience working in global clinical development organization
- Experience in Oncology development
- Experience in outsourcing and oversight
- Direct experience with health authority inspections of clinical supply management
- Knowledge of relevant regulations and guidelines
- Knowledge of appropriate supply chain systems used for forecasting
- Strong vendor management and project management skills
- Leadership skills with the ability to lead cross-functional teams
What We Do
Tango Therapeutics is a biotechnology company discovering and developing novel medicines targeting cancer vulnerabilities to deliver transformational new therapies for patients. Tango was launched in 2017 with a $55 million Series A investment from Third Rock Ventures. The company has established a robust product engine that leverages advances in DNA sequencing and CRISPR-based target discovery to generate breakthrough medicines that have the potential to provide deeper, more sustained benefit than today’s targeted therapies, and extend the benefit of available immuno-oncology agents. Tango Therapeutics is focused on three areas of drug development, each in well-defined patient populations currently lacking effective treatment options, and each with hallmarks of cancer that have not been targeted yet. These include: loss of tumor suppressor gene function; multiple oncogenic drivers; and immune evasion. What fuels each of Tango’s programs is an increasingly sophisticated ability to utilize synthetic lethality - the interaction between two genes that causes cell death when both are inactivated. In cancer cells, one of these genes is inactivated by mutation; the other will be inactivated by a drug. This approach leaves normal cells largely unaffected, with the potential to greatly enhance anti-tumor efficacy and reduce associated toxicity. Tango’s success will be driven by its depth of understanding of the genetic subtypes of cancer, and corresponding insights into novel drug targets and combinations uniquely relevant to each subtype. By shaping discovery efforts in this way, Tango has the potential to reach the clinic quickly, and with a clear plan for identifying the patients most likely to benefit from each new treatment, an approach that could increase both speed and probability of success in translating novel target discoveries into transformational new medicines for patients.
